.png)
In this webinar, Dr. Sarah Opie-Martin and Dr. Paul Wicks discuss the latest research on SOD1 gene variants and their association with ALS. The webinar explores the implications of these findings for the diagnosis and treatment of ALS, and discusses potential avenues for future research.
Clinical trials play a crucial role in the development of pharmaceutical and biotech products. However, unforeseen challenges can arise during the trial process, potentially jeopardising the integrity and outcomes of the study. As a recent Applied Clinical Trial article noted, “while drug discovery is mostly about science, drug development is rich with, and risked by, human drama.”
Data security and privacy are critical considerations in the biotech industry, especially for companies working in genetics.
Patient centricity has become increasingly important in clinical trials for ALS. In this webinar, host Paul Wicks and Cathy Collet discuss the challenges of patient engagement in ALS clinical trials and the potential ways to overcome them.
Genomics-based drug discovery offers great potential for the development of targeted therapies that can offer new and better treatment options for patients. By utilising genetic and biomarker information, this approach allows us to gain insights into the fundamental causes of diseases. But this growing field is not without its challenges.
Last week, our team had the privilege of attending the European Association for the Study of the Liver (EASL) conference, where groundbreaking advancements in liver research were unveiled. The conference provided an exceptional platform for experts and researchers to exchange knowledge and foster collaboration in the field of liver disease. In discussions with fellow conference-goers, our team identified several noteworthy themes emerging as key areas of interest. These included the pivotal role of genetics, particularly the PNPLA3 gene, in driving liver fibrosis in NAFLD/MASLD, the significance of AATD SERPINA 1 - PiZZ genotype pathogenicity, and the nomenclature change in NASH and MASH. Here, we will explore these developments, shedding light on the implications they hold for the future of liver disease research and patient care.
At Sano, we know that measuring and optimising data is the key to successful execution of clinical trials. That’s why we’ve put together a three-page report on key strategies to measure and optimise your data in a way that streamlines your operations. In it, we explore the significance of data collection and integration, real-time analytics, performance metrics, and predictive modelling in the world of clinical trials. Download below to learn more!
This webinar, hosted by Lindsey Wahlstrom-Edwards, Partnerships Lead for Sano Genetics, and featuring Wayne Eskridge and Dr. Neeraj Mistry from the Fatty Liver Foundation, was an informative session on the genetics and lifestyle factors that contribute to metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).
This webinar, moderated by Patrick Short, CEO and co-founder of Sano Genetics, and featuring two panelists, Jessi Keavney and Krista Qualmann, discussed the importance of genetic testing in understanding an individual's risk for Parkinson's disease.
Patient engagement has always been a cornerstone of successful clinical trials. It's a dynamic process that begins long before the trial and continues well after its conclusion. By fostering a strong relationship between researchers and patients, patient engagement can help improve enrollment, boost retention rates, improve the accuracy of data collected, and ensure the trial's overall success. This blog outlines the importance of patient engagement, then introduces the concept of a “Virtual Waiting Room” through which clinical trial sponsors can engage patients throughout the stages and phases of a study.